Tianjin Tianyao Pharmaceuticals (600488.SH): Marketing application for dexamethasone API approved

date
15:36 19/11/2026
avatar
GMT Eight
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it recently received the dexamethasone "Chemical API Marketing Application Approval Notice" issued by the National Medical Products Administration. The drug is mainly used for allergic and autoimmune inflammatory diseases. This approval will further meet the diversified needs of downstream formulation customers, further enrich the company's product portfolio, fully leverage the advantages of API-formulation integration, and help expand the company's business areas.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it recently received the "Chemical API Marketing Application Approval Notice" for dexamethasone issued by the National Medical Products Administration. The drug is mainly used for allergic and autoimmune inflammatory diseases. This approval will further meet the diversified needs of downstream formulation customers, further enrich the company's product portfolio, fully leverage the advantages of API-formulation integration, and help expand the company's business areas.